LEE, CHANGSIK,李昌植,LEE, JAEKWANG,李宰光,SONG, HYESEUNG,宋彗丞,BAE, DAEKWON,裵大权,裵大權,HA, NINA,河妮娜,KIM, IL HYANG,金一香
申请号：
TW105116055
公开号：
TWI617545B
申请日:
2016.05.23
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
The present invention relates to novel Heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel Heterocyclicalkyl derivatives.The novel Heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.本發明係關於具有組織蛋白去乙醯酶(HDAC)抑制活性之新穎雜環烷基衍生物、其光學異構體或其醫藥上可接受之鹽、其用於製備藥劑之用途、含有其之醫藥組合物、使用該組合物治療疾病之方法及製備該等新穎雜環烷基衍生物之方法。本發明之該等新穎雜環烷基衍生物係選擇性組織蛋白去乙醯酶(HDAC)抑制劑，且可有效地用於治療組織蛋白去乙醯酶介導之疾病，例如細胞增殖性疾病、發炎性疾病、體染色體顯性疾病、遺傳性代謝疾病、自體免疫疾病、急性/慢性神經性疾病、肥大、心臟衰竭、眼部疾病或神經退化疾病。
